Verrica Pharmaceuticals Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Verrica Pharmaceuticals Inc. (VRCA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-11
- Verrica Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.24.
- Verrica Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00.
- Verrica Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $15.27, a 1596.67% increase year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $36.16.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | $36.16 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $3.62 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $3.62 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $1.24 10-Q · filed 2024-05-13 | |||
| 2023-09-30 | $0.90 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $0.90 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | |||
| 2021-09-30 | $12.67 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $12.92 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $15.27 10-Q · filed 2021-05-07 | |||
| 2020-09-30 | $7.73 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $0.90 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | $0.90 10-Q · filed 2020-05-07 | |||
| 2019-06-30 | $6.07 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |